eNLife Research Raises $684K to Develop AI-Powered Alzheimer's Detection

eNLife Research, a Bengaluru-based deeptech startup, has successfully raised $684,000 (Rs 6 crore) in a seed funding round. The funding was led by Piper Serica VC Fund and is a significant step forward for the company as it aims to revolutionize early detection of Alzheimer’s disease through its AI-driven blood test.

Company Background and Objectives

Founded in 2025 by Jojo Jacob, Deepak Kumaran Nair, and Anish Mathew, eNLife Research is committed to developing innovative solutions for early detection of neurodegenerative diseases. The startup is working on a blood-based biomarker platform that leverages artificial intelligence to detect Alzheimer's disease well before clinical symptoms manifest. This approach promises to make early detection more accessible and affordable, contrasting with traditional diagnostic methods like PET and MRI scans, which can be costly and invasive.

Funding Round Details

The seed funding round, completed on July 9, 2026, was led by Piper Serica VC Fund. While the round did not disclose additional investors, the involvement of Piper Serica VC Fund underscores the growing interest in healthcare innovations that utilize AI for early disease detection.

Strategic Allocation of Funds

The newly raised funds will be channeled towards several key areas:

  • Development and Validation: eNLife plans to build and validate its biomarker platform, ensuring it meets clinical-grade standards for diagnostic assays.
  • Team Expansion: The company intends to expand its research and development team to accelerate progress.
  • Prototype to Clinical Validation: Funds will also support the transition of the diagnostic assay from prototype to clinical-grade validation, a critical step in bringing the technology to market.

Founders' Vision

Jojo Jacob, Co-Founder and Director of eNLife Research, and his team are driven by a mission to close the gap in Alzheimer’s care. Deepak Kumaran Nair, co-founder of eNLife, remarked: "The biggest failure of Alzheimer’s care today isn’t the absence of treatments in trials; it’s that we find patients a decade too late to use them. We started eNLife to close both gaps at once: detect the disease at the molecular stage."

Future Prospects

With this funding, eNLife Research is poised to make significant strides in the healthcare sector, particularly in the early detection of neurodegenerative diseases. The company’s AI-powered blood test could potentially change how Alzheimer's disease is diagnosed, offering a less invasive, more cost-effective solution that could be implemented widely across diagnostic centers.

As eNLife continues to develop its technology, the healthcare community will be watching closely to see how these innovations might impact early detection and treatment strategies for Alzheimer’s and similar conditions.